nifekalant hydrochloride has been researched along with dexmedetomidine in 1 studies
| Studies (nifekalant hydrochloride) | Trials (nifekalant hydrochloride) | Recent Studies (post-2010) (nifekalant hydrochloride) | Studies (dexmedetomidine) | Trials (dexmedetomidine) | Recent Studies (post-2010) (dexmedetomidine) |
|---|---|---|---|---|---|
| 138 | 16 | 38 | 5,332 | 1,643 | 4,186 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajiki, K; Hayami, N; Kanamori, K; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S | 1 |
1 other study(ies) available for nifekalant hydrochloride and dexmedetomidine
| Article | Year |
|---|---|
Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Arrhythmia Agents; Clonidine; Dexmedetomidine; Disease Models, Animal; Heart Conduction System; Humans; Long QT Syndrome; Methoxamine; Pyrimidinones; Rabbits; Tachycardia | 2012 |